209 related articles for article (PubMed ID: 35154142)
1. The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition.
Donlon NE; Davern M; Sheppard AD; O'Connell F; Dunne MR; Hayes C; Mylod E; Ramjit S; Temperley H; Mac Lean M; Cotter G; Bhardwaj A; Butler C; Conroy MJ; O'Sullivan J; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Front Immunol; 2022; 13():823225. PubMed ID: 35154142
[TBL] [Abstract][Full Text] [Related]
2. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma.
Davern M; Gaughan C; O' Connell F; Moran B; Mylod E; Sheppard AD; Ramjit S; Yun-Tong Kung J; Phelan JJ; Davey MG; Ryan EJ; Butler C; Quinn L; Howard C; Tone E; Phoenix E; Butt WT; Lynam-Lennon N; Maher SG; Ravi N; Donohoe CL; Reynolds JV; Lysaght J; Donlon NE
Front Immunol; 2023; 14():1150754. PubMed ID: 37359545
[TBL] [Abstract][Full Text] [Related]
4. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
5. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
6. Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.
Davern M; Bracken-Clarke D; Donlon NE; Sheppard AD; Connell FO; Heeran AB; Majcher K; Conroy MJ; Mylod E; Butler C; Donohoe C; Donnell DO; Lowery M; Bhardwaj A; Ravi N; Melo AA; Sullivan JO; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6583-6599. PubMed ID: 36790524
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer.
Iams WT; Villaflor VM
World J Surg; 2017 Jul; 41(7):1719-1725. PubMed ID: 28271259
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition.
van den Ende T; Ezdoglian A; Baas LM; Bakker J; Lougheed SM; Harrasser M; Waasdorp C; van Berge Henegouwen MI; Hulshof MCCM; Haj Mohammad N; van Hillegersberg R; Mook S; van der Laken CJ; van Grieken NCT; Derks S; Bijlsma MF; van Laarhoven HWM; de Gruijl TD
Oncoimmunology; 2023; 12(1):2233403. PubMed ID: 37470057
[TBL] [Abstract][Full Text] [Related]
9. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
[TBL] [Abstract][Full Text] [Related]
10. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.
Abdel-Latif MM; O'Riordan JM; Ravi N; Kelleher D; Reynolds JV
Dis Esophagus; 2005; 18(4):246-52. PubMed ID: 16128781
[TBL] [Abstract][Full Text] [Related]
11. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome.
Yamaguchi Y; Hihara J; Hironaka K; Ohshita A; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hamai Y
Oncol Rep; 2006 Apr; 15(4):895-901. PubMed ID: 16525677
[TBL] [Abstract][Full Text] [Related]
12. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
[TBL] [Abstract][Full Text] [Related]
13. Cytokine response following transthoracic and transhiatal esophagectomy in patients with esophageal cancer.
Mahmoodi M; Mir MR; Daryaei P; Harirchi I; Rezaei N; Mohagheghi MA; Mousavi-Jarrahi A; Nahavandian B; Kavianpour M; Jafari A
Eur Cytokine Netw; 2008 Jun; 19(2):92-8. PubMed ID: 18632423
[TBL] [Abstract][Full Text] [Related]
14. [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].
Müller AK; Lenschow C; Palmes D; Senninger N; Hummel R; Lindner K
Chirurg; 2015 Sep; 86(9):874-80. PubMed ID: 25662991
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
16. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
[TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant chemoradiotherapy on perioperative immune function of patients with locally advanced esophageal cancer.
Tan JT; Yang Y; Mao NQ; Liu DS; Huang DM; Pan H; Xie T; Pan Q; Yang L; Zhong JH; Zuo CT
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27766708
[TBL] [Abstract][Full Text] [Related]
19. Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus.
Westerterp M; Boermeester MA; Omloo JM; Hulshof MC; Vervenne WL; Lutter R; Out TA; van Lanschot JJ
Cancer Immunol Immunother; 2008 Dec; 57(12):1837-47. PubMed ID: 18398607
[TBL] [Abstract][Full Text] [Related]
20. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma.
Galvin KC; Conroy MJ; Doyle SL; Dunne MR; Fahey R; Foley E; O'Sullivan KE; Doherty DG; Geoghegan JG; Ravi N; O'Farrelly C; Reynolds JV; Lysaght J
Cancer Lett; 2018 Apr; 418():230-238. PubMed ID: 29339209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
